Capital Allocation Plan

Overall, Adaptive is positioning its MRD diagnostics unit for continued growth and preparing for a potential standalone entity, while leveraging a sizable convertible debt issuance to finance debt repayment, share repurchases, and further MRD expansion. The company’s focus on AI‑driven discovery in Immune Medicine and the strategic separation reflect its intent to pursue optimal capital allocation and value creation for shareholders.